PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9332262

Benign prostatic hyperplasia.

H S Clarke
View original source ↗Export metadata ↓

Abstract

Benign prostatic hyperplasia is a common and costly disease that affects older men. This article reviews the underlying histopathologic changes that cause benign prostatic hyperplasia. The symptoms and systematic evaluation of the patient are described, along with the current therapeutic options for treatment.

Explore related subjects

Adrenergic alpha-AntagonistsAgedFinasterideHumansMaleMiddle AgedProstateProstatectomyProstatic HyperplasiaRandomized Controlled Trials as TopicUrinary BladderUrinationUrination DisordersJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H S Clarke. 1997. Benign prostatic hyperplasia.. https://doi.org/10.1097/00000441-199710000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics.

Psychostimulant-induced locomotor hyperactivity is commonly associated with an inhibition of dopamine reuptake. However, a physiological coupling between noradrenergic and dopaminergic neurons occurring through the stimulation of alpha1-adrenergic receptors has recently been proposed. This possibility was tested on locomotor responses induced either by D-amphetamine and cocaine, which both interfere with noradrenergic and dopaminergic transmissions, or by GBR 12783, a specific dopamine reuptake inhibitor. In an attempt to control the effects of stress and novelty on noradrenergic neurons activity, rats were submitted to habituation procedures consisting of either a 15-h period of habituation to the experimental environment ("long-habituation") or to repeated exposure to intraperitoneal saline injections for 3 consecutive days ("three-session"). Three-session-exposed animals exhibited a pronounced locomotor reactivity to saline injection which did not occur after noradrenergic depletion, clonidine (20 microg/kg) or prazosin (0.5 mg/kg) pretreatments, or in long-habituation-preexposed animals. Cocaine and GBR 12783 locomotor hyperactivities were doubled in three-session vs. long-habituation-preexposed rats, whereas D-amphetamine responses were similar in both conditions. Prazosin (0.5 mg/kg) pretreatment reduced the acute locomotor effects of the three psychostimulants in both procedures and blocked the behavioral sensitization induced by repeated injections of D-amphetamine (0.75 mg/kg) or cocaine (5 mg/kg). GBR 12783 (5 mg/kg) failed to induce significant behavioral sensitization. In addition to their role in the acute and sensitized locomotor responses to psychostimulants possessing different pharmacological characteristics, alpha1-adrenergic receptors are involved in animal reactivity to previously experimented procedures. This suggests an implication of noradrenergic neurons in the vulnerability to psychostimulants.

Adrenergic alpha-Antagonists↗
PubMed2002

Relationship between arterial distensibility and low-frequency power spectrum of blood pressure in spontaneously hypertensive rats.

The aim of this study was to determine in spontaneously hypertensive rats (SHRs) whether a significant association may be observed between the low-frequency component of blood pressure variability (BPV) and arterial distensibility and to evaluate the role of the autonomic nervous system in this relationship. Doxazosin (1 mg/kg/d s.c.), flesinoxan (1 mg/kg/d s.c.), and urapidil (30 mg/kg/d s.c.) were infused over 24 h in SHRs. Blood pressure was recorded in conscious rats and BPV was characterized by spectral analysis. The distensibility-pressure curves for the carotid artery were determined by an ultrasonic echo-tracking device in anesthetized rats. Untreated SHRs had higher mean arterial pressure (MAP) and low-frequency MAP but a lower distensibility than normotensive Wistar-Kyoto rats. In SHRs inhibition of the autonomic nervous system by peripheral blockade of alpha1-adrenoceptors (doxazosin, 1 mg/kg, or urapidil, 30 mg/kg) or centrally mediated reduction of sympathetic tone (flesinoxan, 1 mg/kg) reduced MAP and low-frequency MAP in the conscious state and increased carotid operational distensibility in the anesthetized state. In these SHRs, we observed a negative association between low-frequency MAP and operational distensibility ( r = -0.48, p < 0.01). From multiple regression analysis, MAP and low-frequency MAP, but not drug treatment, influenced arterial distensibility. Our study in SHRs provides evidence for a strong association between increased low-frequency MAP and reduced arterial distensibility, with a common modulation provided by the autonomic nervous system via the alpha 1 -adrenergic receptor component and central nervous system.

Adrenergic alpha-Antagonists↗
PubMed2002

What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.

PURPOSE: In addition to its usefulness as a therapeutic modality, intracavernous injection may also be done in a diagnostic capacity. While a good response to an intracavernous injection test rules out venous leakage, a failed erectile response to the test in the office setting may not be completely representative of the patient erectile state. We determined by quantitative analysis the likely significance of failure to respond to intracavernous injection testing. MATERIALS AND METHODS: Patients evaluated with the standard erectile dysfunction assessment at our andrology clinic between 1996 and 1999 were included in analysis. All 122 patients who did not meet study exclusion criteria underwent a test dose of intracavernous injection with papaverine, phentolamine and prostaglandin E1. Regardless of the response or lack of response to the test the men then underwent nocturnal penile tumescence testing, penile blood flow study and re-dose pharmacocavernosography. Results of these adjunctive tests were compared to the outcome of a papaverine, phentolamine and prostaglandin E1 intracavernous injection test by quantitative analysis. RESULTS: A total of 87 patients failed to respond to the test dose. Average age of the nonresponders versus responders was 46.8 versus 33.8 years. The duration of erectile dysfunction in nonresponders versus responders was 31.0 versus 13.7 months. Poor intracavernous injection responders required an average of 1.9-fold greater induction flow and 6-fold greater maintenance flow than good responders. Receiver operator characteristics (ROC) curve analysis revealed that the best predictors of the intracavernous injection test response were erectile dysfunction duration (ROC 0.99), patient age (ROC 0.87), maintenance flow (ROC 0.86), pressure loss (ROC 0.83) and resistive index (ROC 0.82). The ROC area for peak systolic velocity was 0.69. CONCLUSIONS: Our results indicate that age and erectile dysfunction duration alone are the most important variables affecting the results of an intracavernous injection test. However, in patients older than 40 years with a greater than 2-year history of erectile dysfunction failure to respond to intracavernous injection testing is most closely associated with venous insufficiency, as evidenced by the high ROC values for variables indicative of venous insufficiency, namely maintenance flow, pressure loss and the resistive index. Therefore, nonresponse to an office intracavernous injection test in an older patient with erectile dysfunction of long duration is most likely due to venous leakage. If only 1 confirmatory test is possible, cavernosometry provides the most information.

Adrenergic alpha-Antagonists↗